107 related articles for article (PubMed ID: 21908617)
1. Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway.
Kapeli K; Hurlin PJ
J Biol Chem; 2011 Nov; 286(44):38498-38508. PubMed ID: 21908617
[TBL] [Abstract][Full Text] [Related]
2. Identification of antimycin A as a c-Myc degradation accelerator via high-throughput screening.
Liu Z; Ishikawa K; Sanada E; Semba K; Li J; Li X; Osada H; Watanabe N
J Biol Chem; 2023 Sep; 299(9):105083. PubMed ID: 37495110
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc.
Masaki T; Habara M; Hanaki S; Sato Y; Tomiyasu H; Miki Y; Shimada M
Sci Rep; 2023 Aug; 13(1):13116. PubMed ID: 37573463
[TBL] [Abstract][Full Text] [Related]
4. S146L in MYC is a context-dependent activating substitution in cancer development.
Hinds JW; Feris EJ; Wilkins OM; Deary LT; Wang X; Cole MD
PLoS One; 2022; 17(8):e0272771. PubMed ID: 36018850
[TBL] [Abstract][Full Text] [Related]
5. Missense mutations in Myc Box I influence MYC cellular localization, mRNA partitioning and turnover to promote leukemogenesis.
Arthur NB; Christensen KA; Mannino K; Ruzinova MB; Kumar A; Gruszczynska A; Day RB; Erdmann-Gilmore P; Mi Y; Sprung R; York CR; Reid Townsend R; Spencer DH; Sykes SM; Ferraro F
bioRxiv; 2023 Oct; ():. PubMed ID: 37961226
[TBL] [Abstract][Full Text] [Related]
6. A helicase-independent role of DHX15 promotes MYC stability and acute leukemia cell survival.
Li Q; Guo H; Xu J; Li X; Wang D; Guo Y; Qing G; Van Vlierberghe P; Liu H
iScience; 2024 Jan; 27(1):108571. PubMed ID: 38161423
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Control of Metabolism.
Pavlova NN; Thompson CB
Cold Spring Harb Perspect Med; 2024 Apr; ():. PubMed ID: 38565265
[TBL] [Abstract][Full Text] [Related]
8. Manipulating Myc for reparative regeneration.
Ascanelli C; Dahir R; Wilson CH
Front Cell Dev Biol; 2024; 12():1357589. PubMed ID: 38577503
[TBL] [Abstract][Full Text] [Related]
9. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
10. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma.
Sethi B; Kumar V; Jayasinghe TD; Dong Y; Ronning DR; Zhong HA; Coulter DW; Mahato RI
J Control Release; 2023 Feb; 354():80-90. PubMed ID: 36599397
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.
Almeida J; Mota I; Skoda J; Sousa E; Cidade H; Saraiva L
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551697
[TBL] [Abstract][Full Text] [Related]
13. The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations.
Xiang S; Reed DR; Alexandrow MG
Oncogene; 2023 Feb; 42(7):473-490. PubMed ID: 36522488
[TBL] [Abstract][Full Text] [Related]
14. Interplay: The Essential Role between INSM1 and N-Myc in Aggressive Neuroblastoma.
Chen C; Lan MS
Biology (Basel); 2022 Sep; 11(10):. PubMed ID: 36290282
[TBL] [Abstract][Full Text] [Related]
15. Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases.
Mundo L; Ambrosio MR; Raimondi F; Del Porro L; Guazzo R; Mancini V; Granai M; Jim Rocca B; Lopez C; Bens S; Onyango N; Nyagol J; Abinya N; Navari M; Ndede I; Patel K; Paolo Piccaluga P; Bob R; de Santi MM; Russell RB; Lazzi S; Siebert R; Stein H; Leoncini L
Blood Cancer J; 2019 Nov; 9(12):91. PubMed ID: 31748534
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
Han H; Jain AD; Truica MI; Izquierdo-Ferrer J; Anker JF; Lysy B; Sagar V; Luan Y; Chalmers ZR; Unno K; Mok H; Vatapalli R; Yoo YA; Rodriguez Y; Kandela I; Parker JB; Chakravarti D; Mishra RK; Schiltz GE; Abdulkadir SA
Cancer Cell; 2019 Nov; 36(5):483-497.e15. PubMed ID: 31679823
[TBL] [Abstract][Full Text] [Related]
17. The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.
Higashi M; Sakai K; Fumino S; Aoi S; Furukawa T; Tajiri T
Surg Today; 2019 Sep; 49(9):721-727. PubMed ID: 30848386
[TBL] [Abstract][Full Text] [Related]
18. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract][Full Text] [Related]
19. INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma.
Chen C; Breslin MB; Lan MS
Oncotarget; 2015 Nov; 6(34):36700-12. PubMed ID: 26456864
[TBL] [Abstract][Full Text] [Related]
20. An unexpected role for caspase-2 in neuroblastoma.
Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S
Cell Death Dis; 2014 Aug; 5(8):e1383. PubMed ID: 25144718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
